Trials
20 active
35 in total · 34 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Empagliflozin + Metformin (Diampa™-M): 5mg+500mg, 5mg+850mg, 5mg+1000mg, 12.5mg+1000mg, 12.5mg+500mg, 12.5mg+ 850mg Empagliflozin Alone (Diampa™): 10mg, 25mg”In the company’s words, NCT05164263 on ClinicalTrials.gov
- Tested for
- Type II Diabetes Mellitus, Efficacy, Self, Safety Issues
- Main trialPhase 4
- “Study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population. Study design Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study. Sample size The estimated sample size will be n=156. Duration of study 12 months (data lock point will be completion of 6 months' follow-up from the time of last patient's enrollment date) Safety Assessment: Patient will be monitored for Hypoglycemia, Dehydration, Hypotension, Urinary Tract Infections, Fungal…”In the company’s words, NCT05164263 on ClinicalTrials.gov
- Other names
- Empagliflozin
Other drugs for Type II Diabetes Mellitus
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- QLG1091Qilu Pharmaceutical · Phase 3
- SHR-3167Hengrui · Phase 3
- Maridebart cafraglutideAmgen · Phase 3
- LenbelintideAstraZeneca · Phase 3
Coming up1
- 31 DecPhase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials35
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 31 Dec 2026 | Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study | |
| Phase 4Ended | not given | The effect of empagliflozin on peripheral microvascular dysfunction in heart failure with preserved ejection fraction | |
| Phase 3/4Ended | not given | Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF): the INITIATE-HFrEF randomized open-label trial | |
| Phase 3Authorised | not given | Effect at 3 months of early empagliflozin initiation in cardiogenic shock patients on mortality, rehospitalization, left ventricular ejection fraction and renal function. A randomized multicentric open trial. (EMPASHOCK) | |
| Phase 2Ended | not given | Effects of empagliflozin on plasma glucose in patients with HNF1A-MODY: a randomized, double-blind, crossover trial | |
| Phase 4Ended | not given | EMPagliflozin after Aortic Valve Replacement - the EMPAVR study - a randomized clinical trial | |
| Phase 4Authorised | not given | Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease | |
| Phase 1Ended | not given | Comparative Bioavailability of Empagliflozin 25 mg Film-Coated Tablets: A Single-Dose, Open-Label, Randomized, Two-Sequence, Two-Treatment, Two-Period Crossover Study in Healthy Subjects Under Fasting Conditions. | |
| Phase 4Ended | not given | Optimization of Albuminuria-Lowering Therapies for Individual Patients with Type 2 Diabetes Using Empagliflozin and Finerenone in a Pilot Remote Clinical Trial | |
| Phase 2Ended | not given | Effect of the SGLT2 inhibitor empagliflozin in patients with euvolemic and hypervolemic hyponatremia – a multicentric randomized double-blind placebo-controlled trial (the EMPOWER Study) | |
| Phase 3Authorised | not given | COmbiNed eFfIcacy and safety of an eaRly, intensive MAnagement sTrategy with fInerenOne and SGLT2 iNhibitor in patients hospitalized with Heart Failure (CONFIRMATION-HF) | |
| Phase 3Authorised | not given | BIOmarker driven intensification of cardiovascular RISK factor management in patients with high risk for recurrent cardiovascular EVENTs | |
| Phase 2Ended | not given | The impact of Empagliflozin on Left atrIal Volume and the feasibility of using Fitbit and mHealth to prescribe Exercise in non-diabetic Pre- Heart Failure (ELIVE pre-HF Study) | |
| Phase 2Ended | not given | Evaluation of the efficacy and safety of empagliflozin in the treatment of neutropenia in patients with glycogenosis Ib. EMPAtia. | |
| Phase 2Authorised | not given | Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes: A Randomized Open Intervention Study That Compares Empagliflozin, Pioglitazone and Semaglutide (DiaSpax) | |
| Phase 2Ended | not given | Acute effects of SGLT2 inhibitor on kidney allograft oxygen tension: A randomized, double-blind, placebo controlled crossover trial | |
| Phase 4Authorised | not given | Acetazolamide in combination with SGLT2i in patients with volume overload and acute heart failure | |
| Phase 3Authorised | not given | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to evaluate Efficacy and Safety of Empagliflozin in the prevention of Cardiotoxicity in Cancer patients undergoing Chemotherapy based on Anthracyclines (EMPACT study) | |
| Phase 2Halted | not given | Proof-of-concept study of Empagliflozin in patients with pulmonary arterial hypertension (EmPAH) | |
| Phase 3Ended | not given | The use of empagliflozin in patients with hypertrophic cardiomyopathy | |
| Phase 3Authorised | not given | Effects of continued administration of empagliflozin in patients with heart failure on active SGLT2 inhibitor treatment admitted for acute decompensated heart failure | |
| Phase 4Authorised | not given | Reducing Non-Alcoholic Steatohepatitis | |
| Phase 3Authorised | not given | EMpagliflozin and daPAgliflozin in patients hospiTalized for acute decompensated Heart failure (EMPATHY) – a phase III Trial | |
| Phase 4Ended | not given | Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. A pragmatic, phase IV, multicenter, open-label, randomised controlled trial. | |
| Phase 3Authorised | not given | Prevention of cardiac surgery-associated acute kidney injury through the use of sodium-glucose cotransporter 2 inhibitors | |
| Phase 4Authorised | not given | Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (PopS-HF Trial) | |
| Phase 4Ended | not given | Open-label, double-arm, controlled, randomized, multicentre clinical trial to evaluate the impact of pharmacogenetic-guided treatment in patients with insufficiently controlled type 2 diabetes | |
| Phase 4Ended | not given | SGLT-2i, Heart, Improvement of Cardiovascular Autonomic Neuropathy | |
| Phase 3/4Authorised | not given | Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testing, who have exhibited super-response to cardiac resynchronization therapy. DRUGLESS-CRT clinical trial. | |
| Phase 3Authorised | not given | Effect of Empagliflozin in patients with eGFR between 10 and 20 ml/min/1.73m2 - EMPA [10-20] | |
| Phase 4Authorised | not given | A prospective, randomized, controlled clinical pilot trial investigating the partial down-titration of guideline-directed medical therapy in patients with heart failure in remission | |
| Phase 3Authorised | not given | Sodium-glucose cotransporter-2 inhibitors to stABiLizE coronary atherosclerosis pro-gression after acute Myocardial Infarction in women and men with diabetes mellitus | |
| Phase 4Authorised | not given | Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes – DISCO Study | |
| Phase 3Authorised | not given | A phase III, randomized, prospective, double-blind, parallel design, multi-arm, multicenter study to compare the efficacy and safety of alogliptin and empagliflozin combination therapy versus alogliptin alone and empagliflozin alone in metformin-treated participants with type 2 diabetes mellitus and insufficient glycemic control despite diet and exercise (ODISSEIA 2026). | |
| Phase 2/3Authorised | not given | The GranStone Trial - Prevention of Kidney Stones due to Paraffin Oil Induced Granuloma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026